日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Revolutionizing Patient-Reported Outcomes Analysis for Oncology Drug Development Using Population Models

利用群体模型革新肿瘤药物研发中的患者报告结局分析

Zhou, Jiawei; Muluneh, Benyam; Li, Quefeng; Hughes, Jim H

Population Modeling of Factor IX Activity Following Administration of Fidanacogene Elaparvovec Gene Therapy in Participants with Hemophilia B

在接受 Fidanacogene Elaparvovec 基因治疗的 B 型血友病患者中,因子 IX 活性的群体建模

Wojciechowski, Jessica; Gaitonde, Puneet; Hughes, Jim H; Ravva, Patanjali

Population pharmacokinetic modeling of zavegepant, a calcitonin gene-related peptide receptor antagonist, in healthy adults and patients with migraine

在健康成人和偏头痛患者中,对降钙素基因相关肽受体拮抗剂扎维吉泮进行群体药代动力学建模

Comisar, Craig M; Francis, Jose; Hughes, Jim H; Bhardwaj, Rajinder; Bertz, Richard; Liu, Jing

Exposure-response modeling of liver fat imaging endpoints in non-alcoholic fatty liver disease populations administered ervogastat alone and co-administered with clesacostat

在非酒精性脂肪肝患者中,单独使用ervogastat以及与clesacostat联合使用时,对肝脏脂肪成像终点进行暴露-反应建模。

Hughes, Jim H; Amin, Neeta B; Wojciechowski, Jessica; Vourvahis, Manoli

Population Pharmacokinetic Modeling of the Oral Calcitonin Gene-Related Peptide Receptor Antagonist Rimegepant in Adults

口服降钙素基因相关肽受体拮抗剂瑞美吉泮在成人中的群体药代动力学模型

Comisar, Craig M; Hughes, Jim H; Francis, Jose; Chinda, Yorinao; Sano, Yamato; Muto, Chieko; Neumar, Christine; Bhardwaj, Rajinder; Bertz, Richard; Liu, Jing

Exposure Matching Using Population Pharmacokinetic Modeling and Simulation to Support Rimegepant Dose Selection for Pediatric Patients With Migraine

利用群体药代动力学建模和模拟进行暴露匹配,以支持瑞美吉泮在偏头痛儿科患者中的剂量选择

Comisar, Craig M; Hughes, Jim H; Mo, Gary; Bhardwaj, Rajinder; Jakate, Abhijeet; Lim, Chay Ngee; Liu, Jing

From Symptom to Outcome: Defining Clinically Meaningful Patient-Reported Appetite Loss in Non-Small-Cell Lung Cancer

从症状到结局:定义非小细胞肺癌中具有临床意义的患者自述食欲减退

Zhou, Jiawei; Muluneh, Benyam; Li, Quefeng; Wagner, Lynne I; Wang, Yuchen; Hughes, Jim H

Concentration-QTc and cardiac safety analysis of single and multiple zavegepant nasal spray doses in healthy participants to support approval

在健康受试者中开展单次和多次使用扎维泮鼻喷雾剂的浓度-QTc间期和心脏安全性分析,以支持其批准上市。

Hughes, Jim H; Bertz, Richard; Bhardwaj, Rajinder; Donohue, Mary K; Madonia, Jennifer; Anderson, Matt S; Morris, Beth A; Croop, Robert S; Liu, Jing

Towards adaptive technology in routine mental health care

迈向日常心理健康护理中的适应性技术

Lamo, Yngve; Mukhiya, Suresh K; Rabbi, Fazle; Aminifar, Amin; Lillehaug, Svein I; Tørresen, Jim; H Pham, Minh; Côtè-Allard, Ulysse; Noori, Farzan M; Guribye, Frode; Inal, Yavuz; Flobakk, Eivind; Wake, Jo D; Myklebost, Sunniva; Lundervold, Astri J; Hammar, Aasa; Nordby, Emilie; Kahlon, Smiti; Kenter, Robin; Sekse, Ragnhild Jt; Griffin, Kristine F; Jakobsen, Petter; Ødegaard, Ketil Joachim; Skar, Yngvar S; Nordgreen, Tine

Your best day: An interactive app to translate how time reallocations within a 24-hour day are associated with health measures

你的最佳一天:一款互动应用程序,用于解读24小时内时间重新分配与健康指标之间的关联。

Dumuid, Dorothea; Olds, Timothy; Wake, Melissa; Lund Rasmussen, Charlotte; Pedišić, Željko; Hughes, Jim H; Foster, David Jr; Walmsley, Rosemary; Atkin, Andrew J; Straker, Leon; Fraysse, Francois; Smith, Ross T; Neumann, Frank; Kenett, Ron S; Jarle Mork, Paul; Bennett, Derrick; Doherty, Aiden; Stanford, Ty